No Data
Shapuaisi Pharmaceutical Shareholders Plan to Reduce Stakes; Shares Down 10%
November 22nd A-share investment lightning rod︱Changguang Huaxin: Shareholders Guotou Chuangye Ningbo Fund, Yili Suxin, and Nanjing Daofeng plan to collectively reduce their shareholding by no more than 2.01%.
*Shenzhen Coship Electronics: Termination of the application for reorganization and pre-reorganization to the court.
Zhejiang Shapuaisi Pharmaceutical (603168.SH): Chen Dekang and Shanghai Jingxing plan to collectively reduce their shareholding by no more than 5%.
According to Gelonghui on November 21, zhejiang shapuaisi pharmaceutical (603168.SH) announced that Mr. Chen Dekang plans to reduce his shareholding due to personal fund needs. Starting from the date of this announcement, within three months after 15 trading days, from December 13, 2024, to March 12, 2025, he will reduce no more than 3,791,616 shares through centralized bidding trading, which does not exceed 1.00% of the company's total share capital; within three months after the 15 trading days from the date of the announcement, no more than 3,791,616 shares will be reduced through block trading, which also does not exceed 1.00% of the company's total share capital.
Zhejiang Shapuaisi Pharmaceutical (603168.SH): obtained the Tobramycin Eye Drops "Pharmaceutical Registration Certificate".
Glory 11th November | Zhejiang Shapuaisi (603168.SH) announced that the company has received the "Drug Registration Certificate" issued by the National Medical Products Administration for Tobramycin Eye Drops. The approved Tobramycin Eye Drops are suitable for local anti-infective treatment of sensitive strains of bacteria infecting the external eye and its adnexa.
Sharp Ace: Sharp Ace Report for the Third Quarter of 2024
Sharp Ace 2024 Third Quarter Report
What Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.'s (SHSE:603168) 27% Share Price Gain Is Not Telling YouNo Data
No Data
